Bivalirudin during percutaneous coronary interventions in patients with ST segment elevation myocardial infarction

Acute Card Care. 2010 Jun;12(2):75-6. doi: 10.3109/17482941003732741.

Abstract

Bivalirudin is a direct thrombin inhibitor that seems to be a promising anticoagulation treatment in patient with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We discuss several issues that were raised from the use of Bivalirudin during primary PCI.

Publication types

  • Letter

MeSH terms

  • Angioplasty, Balloon, Coronary*
  • Anticoagulants / therapeutic use*
  • Hirudins
  • Humans
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / mortality
  • Myocardial Infarction / therapy*
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Reproducibility of Results
  • Research Design

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • bivalirudin